Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MaxCyte ( (MXCT) ) has issued an announcement.
MaxCyte, Inc. announced a change in its major holdings, with BlackRock, Inc. increasing its voting rights in the company to 9.98%. This adjustment in BlackRock’s stake could potentially influence MaxCyte’s strategic decisions and market positioning, reflecting confidence from a significant institutional investor.
More about MaxCyte
MaxCyte, Inc. operates in the biotechnology industry, focusing on cell-based therapies and providing cell-engineering platforms. The company is known for its proprietary flow electroporation technology, which is used in the development of advanced medicines.
Find detailed analytics on MXCT stock on TipRanks’ Stock Analysis page.